Skip to content
Sign in
SWC 2026 FinalistGrand Final: Main Stage

Neurosoft Bioelectronics

EPFL spin-off making soft, stretchable cortical electrodes for minimally invasive brain interfaces, with first-in-human epilepsy data and a $7.5M seed.

Geneva, Switzerland, EuropeMedTech & devices, Neurotechnology / brain-computer interfacesStartup World Cup Las Vegas 2026 (CES, 7 Jan. 2026)
Stage
SeedAI integrated
Product
PilotPilots / LOIs
Funding raised
$13.8Mdisclosed
Founded
20206 years ago
Founders
3Nicolas, Florian…
Global score
4.3Grade DRank 76 of 151

Overview

EPFL spin-off based at the Campus Biotech in Geneva (subsidiary in New York) developing minimally invasive neural interfaces for monitoring and treating neurological disorders.

Traction

Pilots / LOIs

Experimental devices not on the market; first-in-human evaluation (soft ECoG in epilepsy surgery) published, 26 papers and 29 patents.

Market

Brain-computer interfaces (BCI)

Neural interfaces are used today for epilepsy monitoring and surgery, and are moving toward therapeutic brain-computer interfaces. Soft electrodes that conform to the brain could reduce tissue damage and improve signal stability. Buyers are hospitals (neurosurgery, epilepsy centres) and, later, payers. The regulatory path (Class III) is long and costly.

Addressable market

2025
$2.4B
2030
$5B
+15.8% a year

Brain-computer interfaces: $2.41bn in 2025, +15.8%/year, ~$5bn in 2030 (ResearchAndMarkets).

Customers

Neurosurgery and epilepsy centres, BCI programmes, research hospitals

Who signs the cheque

Hospital neurosurgery departments, payers (later), medtech partners

Geographies

  • Switzerland
  • United States

Drivers

  • Epilepsy surgery monitoring needs
  • BCI investment momentum
  • Demand for less invasive implants

Headwinds

  • Class III regulation
  • No revenue in the medium term
  • Competitive BCI field

ResearchAndMarkets values BCIs at $2.41bn in 2025 and $12.11bn in 2035 (CAGR 15.8%); 2030 extrapolated at ~$5bn (Grand View: $6.52bn in 2030).

Scalability 4/10. Neural implant subject to long clinical trials and certification in each jurisdiction; highly specialized production.

Market source: businesswire.com

Technology

Category

Neurotechnology – implantable medical device

AI integratedMachine learning / predictive

Maturity

  1. R&D
  2. Prototype
  3. Pilot
  4. On the market
  5. Scaling

pilot

How it works

Soft, stretchable cortical electrodes (SoftECoG) made of elastic materials are implanted minimally invasively and designed for industrial production. AI extracts information such as speech intentions from recordings.

Moat

Strong: 29 patents, 26 papers and first-in-human data.

Differentiation

Soft materials conforming to brain tissue vs rigid electrode grids.

Integration points

  • Neural recording electronics
  • Epilepsy monitoring workflows
  • BCI decoding software
  • Home seizure monitoring

Depends on

  • Clinical trials and Class III approval
  • Manufacturing scale-up
  • Hospital partners

Use of AI

AI extracts information from the soft electrodes' brain recordings (e.g. speech intentions).

Product in detail

Soft, stretchable cortical electrodes (SoftECoG) made of elastic materials, implantable in a minimally invasive way and suitable for industrial production.

Business

Model
Medical device sales after approval; possible partnerships.
Revenue logic
Per-implant pricing with procedure reimbursement (future).
Go-to-market
Clinical partnerships, then hospital sales; New York subsidiary.

Next milestones

  1. First regulatory clearance for diagnostic use
  2. Expanded clinical study
  3. Series A

Key risks

  • Regulatory timeline
  • Capital needs
  • Competition

Opportunities

4 found in the network

Concrete moves for Neurosoft Bioelectronics inside the network: who to sell to, sell through, build with or raise from, each with the reasoning, the evidence and the first step.

  • Distribution 1
  • Co-development 1
  • Investors 2

Distribution1

A channel or customer base to reach together

Offer epilepsy centres a continuum from surgery to home monitoring

Epilepsy centres using Neurosoft electrodes also follow patients at home; Lampsy's contactless seizure lamp covers night-time monitoring. Joint presence in centres strengthens both clinical relationships.

20%confidence

Evidence from the records

  • “Bedside lamp with sensors and AI for contactless seizure detection (claimed accuracy of 99%, company figure).”
  • “first-in-human evaluation (soft ECoG in epilepsy surgery) published, 26 papers and 29 patents.”
If it works
Shared clinical partners and a joint observational study.
First step
Introduce Lampsy to one partner epilepsy centre.

Co-development1

An integration or joint product

Pair soft electrodes with high-density CMOS readout

Corticale's CMOS probes integrate 1,024 active electrodes; combining active readout electronics with Neurosoft's soft substrates could raise channel counts. Both are European spin-offs that could share an EU research grant.

25%confidence

Evidence from the records

  • “SiNAPS probe on a CMOS chip with 1,024 independent active electrodes spaced 30 µm apart.”
  • “Soft, stretchable cortical electrodes (SoftECoG) made of elastic materials, implantable in a minimally invasive way and suitable for industrial production.”
If it works
A joint EU proposal and a readout-electronics roadmap.
First step
Hold a CTO-to-CTO technical call.

Investors2

A fund whose thesis fits

Apply for EIC grant-plus-equity for the next stage

The EIC invests up to $33M in European deep tech and medtech, well suited to Class III device development. Lampsy Health and Leitspalt in the network are EIC-backed.

35%confidence

Evidence from the records

  • “Close the funding gap for breakthrough technologies in Europe by taking strategic risk and crowding in private capital.”
  • “High risk: long and costly Class III regulatory path despite US$13.8M raised.”
If it works
Large non-dilutive plus equity funding.
First step
Prepare an EIC Accelerator short proposal.

Approach Sands Capital for the Series A via PolyJoule

Sands Capital invests at Series A and later in medtech globally. PolyJoule is reportedly backed by Sands in the network, giving a warm path.

25%confidence

Evidence from the records

  • “Sands Capital Ventures and others (according to aggregators)”
  • “29 patents and solid publications”
If it works
A global growth investor for the Series A.
First step
Ask PolyJoule's CEO for an introduction.

Analyst reading of 21 Nov 2026, from the public record of the network. Method: analyst-ai.

Investors that fit

Life-sciences and venture arm of Sands Capital ($54B+ AUM); Pulse strategy ($1.3B) backs therapeutics, diagnostics, devices and tools.

EPFL neural-interface company with first-in-human data, 29 patents and a $7.5M oversubscribed seed; a candidate for a medtech Series A.

40%confidence

Evidence from the records

  • “first-in-human evaluation (soft ECoG in epilepsy surgery) published, 26 papers and 29 patents”
  • “Neurotechnology / brain-computer interfaces”
Intro path
Co-investors PL Capital, Skybound, Connecticut Innovations.
First step
Track Neurosoft's Series A timing and introduce the Pulse team.

San Francisco early-stage investor pairing technology with science: drug discovery, climate, neurotech and lab automation (ZymoChem).

Soft brain-computer interface electrodes with first-in-human data: neurotech fit, but Swiss and US$13.8M raised.

30%confidence

Evidence from the records

  • “Neurotechnology / brain-computer interfaces”
  • “first-in-human evaluation”
Intro path
Connecticut Innovations (Neurosoft investor, US)
First step
Pitch Breakout if US operations expand.

Investment analysis

4.3D

Grade D

Rank 76 of 151

Disruption8.0/10
Business model2.0/10
Market4.0/10
Risk(lower is better)8.0/10

Global score = mean of disruption, model, market and (11 − risk). Last updated 21 Nov 2026.

High-quality neuro deep tech, but a long horizon: speculative.

Disruption

8/10

Soft, minimally invasive neural interfaces from EPFL: breakthrough technology.

Business model

2/10

Experimental devices not on the market, first-in-human evaluation published.

Market

4/10

Score 4/10: TAM $2.41bn → base 4; scalability 4/10 (−1); presence in Switzerland and subsidiary in New York (+1).

Risk

8/10

Lower is better

High risk: long and costly Class III regulatory path despite US$13.8M raised.

Strengths

  • 29 patents and solid publications
  • First human data

Risks

  • No revenue in the medium term
  • Heavy regulation

Funding

$13.8M, disclosed
  1. 2021

    Prize (Venture Kick)CHF 150,000

    Venture Kick

  2. 2022

    Funding round (pre-seed)CHF 3M

    not specified (earlier sources)

  3. non précisée

    Grant (Innosuisse Swiss Accelerator)CHF 2.5M

    Innosuisse

  4. 2026-05

    Seed (oversubscribed)US$7.5M

    Skybound Venture Capital (lead), Protocol Labs (PL Capital), IAG Capital Partners, Connecticut Innovations

Amount used in the study. CHF 3M pre-seed + $7.5M seed + CHF 2.5M Innosuisse + CHF 150K Venture Kick; range $7.7M (Seedtable) to >$20M (GGBA).

Note. > US$20M in total according to GGBA/Business Wire (Seedtable: ≈ $7.7M)

verified, nothing to correct ($7.5M seed in May 2026 led by Skybound VC confirmed; some sources give €6.5M or $8M)

Team

  • Nicolas Vachicouras

    Co-founder & CEO

    EPFL PhD (Stéphanie Lacour's lab, soft bioelectronic interfaces), Swiss "Venture Leader".

  • Florian Fallegger

    Co-founder, CTO (CSO according to VentureLab 2026)

    Researcher from EPFL's Laboratory of Soft Bioelectronic Interfaces, previously at the Wyss Center.

  • Ludovic Serex

    Co-founder, COO (CTO according to VentureLab 2026)

    EPFL engineer, co-founder cited by Venture Kick and VentureLab.

Sources

Regional final
Startup World Cup Las Vegas 2026 (CES, 7 Jan. 2026)
Identification confidence
high
Founding year: 2020 (medium confidence)
Co-founded in 2020 (EPFL spin-off) according to GGBA and Venture Kick; Swiss commercial register entry date not verified ggba.swiss
  1. 1businesswire.com/news/home/20260113892988/en
  2. 2businesswire.com/news/home/20260520357988/en/
  3. 3ggba.swiss/en/neurosoft-bioelectronics-raises-usd-7-5-million-to-advan
  4. 4bioalps.org/neurosoft-bioelectronics-geneva-raises-3million
  5. 5venturelab.swiss/Neurosoft-Bioelectronics-raises-USD-75M-Seed-round-for-brai
  6. 6pulse2.com/neurosoft-bioelectronics-7-5-million-seed-round-closed-to-a

From the open study Startup World Cup 2026 by TIBOK, based on public sources, verified in November 2026. Scores are an analyst's judgment on an explicit grid, not the jury's.

Wall

Wall

No posts yet